Biogen Inc. (VIE:BIIB)
Austria · Delayed Price · Currency is EUR | Market Cap | 26.58B +63.1% |
| Revenue (ttm) | 8.78B +0.3% |
| Net Income | 730.53M -45.5% |
| EPS | 4.94 -46.1% |
| Shares Out | n/a |
| PE Ratio | 36.38 |
| Forward PE | 15.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 179.18 |
| Previous Close | 176.64 |
| Day's Range | 177.18 - 179.46 |
| 52-Week Range | 109.45 - 191.04 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial numbers in USD Financial StatementsNews
Biogen completes acquisition of RayThera
Biogen (BIIB) announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. “The ac...
Biogen Completes Acquisition of RayThera Inc.
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on dis...
Biogen price target raised to $241 from $221 at Mizuho
Mizuho analyst Salim Syed raised the firm’s price target on Biogen (BIIB) to $241 from $221 and keeps an Outperform rating on the shares.
Biogen price target raised to $215 from $200 at Citi
Citi raised the firm’s price target on Biogen (BIIB) to $215 from $200 and keeps a Neutral rating on the shares. The firm updated models in the biotechnology space post…
Biogen price target raised to $231 from $222 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Biogen (BIIB) to $231 from $222 and keeps an Equal Weight rating on the shares.
Biogen price target raised to $251 from $237 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Biogen (BIIB) to $251 from $237 and keeps a Buy rating on the shares. The firm revisited its penetration assumption across Leqembi,…
Biogen price target lowered to $240 from $242 at RBC Capital
RBC Capital lowered the firm’s price target on Biogen (BIIB) to $240 from $242 and keeps an Outperform rating on the shares. The company reported a very solid commercial quarter,…
Biogen price target raised to $240 from $225 at UBS
UBS raised the firm’s price target on Biogen (BIIB) to $240 from $225 and keeps a Buy rating on the shares.
Biogen price target raised to $215 from $201 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Biogen (BIIB) to $215 from $201 and keeps a Neutral rating on the shares. Overall, the firm sees a solid…
Biogen price target raised to $219 from $215 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Biogen (BIIB) to $219 from $215 and keeps a Neutral rating on the shares. Biogen’s Q2 was “solid” by most…
Biogen price target raised to $225 from $215 at TD Cowen
TD Cowen analyst Phil Nadeau raised the firm’s price target on Biogen (BIIB) to $225 from $215 and keeps a Buy rating on the shares. The firm noted they reported…
Biogen price target raised to $248 from $245 at Canaccord
Canaccord raised the firm’s price target on Biogen (BIIB) to $248 from $245 and keeps a Buy rating on the shares. The firm noted they are pleased by yet another…
Biogen Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth, driven by the expanding growth portfolio and successful integration of Apellis products. The company raised its full-year guidance, highlighted robust late-stage pipeline progress, and expects continued top- and bottom-line growth, with key data readouts and product launches ahead.
Biogen Slides: Q2 2026
Biogen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Biogen Earnings release: Q2 2026
Biogen released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Biogen Quarterly report: Q2 2026
Biogen has published its Q2 2026 quarterly earnings report on July 29, 2026.
Biogen Cuts FY Adjusted View as Profit Declines
Biogen's second-quarter profit plummeted and the biopharmaceutical company cut its full-year adjusted earnings forecast.
Biogen lowers FY26 EPS view to $12.00-$13.00 from $14.25-$15.25
Consensus $11.82. Full year total revenue is now expected to increase by a mid-single digit percentage for 2026 as compared to 2025 driven by continued revenue growth from our Growth…
Biogen reports Q2 EPS $3.60, consensus $2.05
Reports Q2 revenue $2.736B, consensus $2.46B. “This quarter is a reflection of the significant progress Biogen (BIIB) has made repositioning the company for long term growth. Not only did our…
Biogen beats quarterly estimates as newer drugs fuel growth
Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand for its rare-disease medicines, while sales of its legacy multiple sclerosis ...
Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs
Biogen's growth portfolio, which includes one closely watched Alzheimer's drug, is a bright spot in the second quarter.
Biogen price target raised to $200 from $185 at Barclays
Barclays raised the firm’s price target on Biogen (BIIB) to $200 from $185 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the biopharmaceuticals space…
Biogen price target raised to $280 from $260 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Biogen (BIIB) to $280 from $260 and keeps a Buy rating on the shares. The firm is revising some of…
Biogen price target lowered to $215 from $217 at BofA
BofA lowered the firm’s price target on Biogen (BIIB) to $215 from $217 and keeps a Neutral rating on the shares. Q2 results, while “unlikely to generate the same headlines”…
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. CHICAGO, July 16, 2026 /PRNewswire/ -- Synapticure, ...